The Atlantic has a great piece today about why the medtech and biotech industries are losing the backing of Silicon Valley investors.
The writer, Allan May, who founded and chairs Life Science Angels and serves as chairman of the Kauffman Angel Resource Institute, says the industry receives around a third of all angel and venture capital investments. These funds, he says, are critical to innovation in the industries, but the money is going away.
May cites three reasons:
- VC firms and capital are down two-thirds since the 2008 financial crisis.